Amphastar Pharmaceuticals, Inc. AMPH
26.13
(0.14)
(0.53%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 15.0×
Follow AMPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.60 | 11.46 | 12.75 | 11.29 |
+8 more quarters Free account |
P/S ratio |
1.21 | 1.23 | 1.74 | 1.71 | |
P/FCF ratio |
5.85 | 6.69 | 10.53 | 11.17 | |
P/Operating CF |
17.16 | 18.56 | 38.09 | 23.55 | |
P/B ratio |
1.15 | 1.15 | 1.59 | 1.59 | |
Price to Tangible BV |
7.32 | 4.15 | 5.62 | 6.06 | |
EV/Sales |
1.64 | 1.67 | 2.19 | 2.17 | |
EV/EBITDA |
6.87 | 6.79 | 7.87 | 7.51 | |
EV/Operating CF |
6.50 | 7.14 | 10.10 | 10.31 | |
EV/FCF |
7.98 | 9.07 | 13.27 | 14.16 | |
Quick Ratio |
1.67 | 2.75 | 2.82 | 2.08 | |
Current Ratio |
2.40 | 3.85 | 4.02 | 3.12 | |
Net Debt/EBITDA |
5.82 | 11.03 | 6.40 | 8.20 | |
Debt/Assets |
35.10% | 37.10% | 37.46% | 36.58% | |
Debt/Equity |
0.80 | 0.79 | 0.77 | 0.78 | |
Asset Turnover |
0.43 | 0.44 | 0.45 | 0.45 | |
Operating CF/Net income |
1.69 | 7.45 | 1.35 | 3.03 | |
Capex/Depreciation |
(0.57) | (0.63) | (0.54) | (0.36) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.05% | 15.62% | 12.73% | 11.65% | |
Selling, General and Administrative Expense of Revenue |
17.17% | 17.50% | 14.61% | 26.57% | |
Intangible Assets out of Total Assets |
0.37 | 0.34 | 0.35 | 0.34 | |
Share Based Compensation of Revenue |
3.86% | 5.42% | 3.39% | 3.28% | |
Graham Net Nets |
(0.39) | (0.27) | (0.16) | (0.20) | |
Graham Number |
26.25 | 25.62 | 28.24 | 29.79 | |
Earnings Yield |
8.62% | 8.73% | 7.84% | 8.86% | |
Free Cash Flow Yield |
17.09% | 14.96% | 9.49% | 8.95% | |
Revenue per Share |
4.21 | 3.78 | 3.92 | 4.13 | |
Operating CF per Share |
1.18 | 1.06 | 0.70 | 1.13 | |
Capex per Share |
(0.20) | (0.21) | (0.18) | (0.12) | |
Free Cash Flow per Share |
0.98 | 0.85 | 0.53 | 1.02 | |
Cash per Share |
6.70 | 6.50 | 6.10 | 6.00 | |
Shareholders Equity per Share |
17.60 | 17.06 | 16.88 | 16.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.60 | 17.06 | 16.88 | 16.71 | |
Free Cash Flow |
42.73 | 38.33 | 24.59 | 47.24 | |
Working Capital |
367.75 | 469.21 | 477.86 | 434.24 | |
Capital Expenditures |
(8.59) | (9.51) | (8.27) | (5.35) | |
Net Current Asset Value |
(344.66) | (241.09) | (204.48) | (250.01) | |
EV/EBIT |
10.50 | 10.32 | 11.23 | 10.47 | |
Capex to Sales |
0.05 | 0.06 | 0.05 | 0.03 | |
Net Profit Margin |
16.50% | 3.75% | 13.34% | 9.04% | |
Price to Operating Income |
7.71 | 7.61 | 8.92 | 8.26 | |
| Other line items | |||||
Average Receivables |
141.04 | 151.42 | 149.38 | 146.93 | |
Average Payables |
208.96 | 164.31 | 152.70 | 172.06 | |
Average Inventory |
185.82 | 177.84 | 165.32 | 158.12 | |
Average Assets |
1,679.55 | 1,637.22 | 1,603.38 | 1,605.70 | |
Average Common Equity |
762.82 | 762.34 | 760.55 | 752.21 |
Columns are period end dates